Patellar tendinopathy (jumper's knee) Musculoskeletal Diseases
Conditions
Interventions
PRP, autologous blood or saline injection
Blood (54cc) will be extracted from the elbow vein in every patient, because this is necessary to obtain 6cc PRP. The liquid to be injected will be placed i
Sponsors
Biomet Europe B.V. (Netherlands)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Jumper?s knee patients aged 18-55 2. Pain at the inferior pole of the patella for more than 3 months 3. Tendinosis or thickening compared to the contralateral side of > 3mm, detected with ultrasonography or MRI 4. Already undergone eccentric training for 6 weeks following a standardized protocol
Exclusion criteria
Exclusion criteria: 1. Pregnancy 2. Injection in the patellar tendon in the last 3 months, irrespective of the applied substance 3. Operation on the patellar tendon in the past 4. At examination indications for intra articular pathology or patellofemoral pain syndrome 5. Chronic NSAID use in the last 3 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| VISA-P ? a validated questionnaire for patellar tendinopathy which assesses pain and function of the knee (100 = maximal score, indicating a normal functional knee, 0 = minimal score). This will be assessed at baseline, 6, 12, 26 and 52 weeks after injection treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Ultrasound abnormalities (tendinosis zone, thickness of tendon and degree of neovascularisation) at baseline and 12 weeks after injection 2. Pain, measured using Visual Analogue Scale (VAS) score (0 = no pain, 10 = unbearable pain) 3. Costs of the treatments 4. Return to sport (level and duration) | — |
Countries
Netherlands
Outcome results
None listed